Best Options Strategy for AGIO
Looking for the best options strategy for Agios Pharmaceuticals, Inc. (AGIO)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live AGIO option chain right now, and a simple map from your view on AGIO to the strategy that fits it. Model any of them in the calculator before you trade.
About AGIO
Agios Pharmaceuticals, Inc. (AGIO) is a major company in Biotechnology. Options traders on AGIO tend to watch , since these can drive large moves in the share price.
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals develops drugs focused on cellular metabolism disorders. Its main approved product is PYRUKYND, a pyruvate kinase activator used to treat hemolytic anemias caused by PK deficiency in adults. The company is also advancing PYRUKYND through late-stage testing for sickle cell disease and exploring it in pediatric PK deficiency patients. Beyond that, Agios markets AQVESME for thalassemia patients who may or may not require regular blood transfusions. The pipeline includes several other candidates at earlier development stages: tebapivat for myelodysplastic syndrome and sickle cell disease, AG-181 for phenylketonuria, and AG-236, an RNA interference therapy licensed from Alnylam, targeting polycythemia vera.
The company generates revenue primarily from PYRUKYND and AQVESME sales in the United States market. These products address rare blood disorders affecting smaller patient populations, which typically support premium pricing models. Agios operates as a biopharmaceutical company rather than a manufacturer, meaning it relies on product commercialization and licensing arrangements rather than broad consumer distribution. Founded in 2007 and based in Cambridge,…
Today's top-scoring strategy for AGIO
Our engine ranks defined-risk strategies on the live AGIO chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $33 | $0.04 |
| Sell | 1× | PUT | $35 | $0.25 |
| Sell | 1× | CALL | $39 | $0.26 |
| Buy | 1× | CALL | $41 | $0.04 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at AGIO's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
AGIO is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on AGIO currently price in about 32% implied volatility, versus roughly 49% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$2.34 (±6%) in AGIO by 2026-07-17 — a range of roughly $34.65 to $39.33. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on AGIO trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Earnings & IV crush
AGIO's next earnings report is due around July 30, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $2.2B
- Beta (vs market)
- 0.59
- 52-week range
- $22.24–$46.00 (62% up the range)
- Short interest
- 11.7% of float · 7.3 days to cover
With 11.7% of AGIO's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for AGIO
Start with your outlook on AGIO, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while AGIO stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open AGIO in the free calculator →
Frequently asked questions
What is the best options strategy for AGIO?
It depends on your outlook. Bullish traders often use a long call or bull call spread on AGIO; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are AGIO options liquid enough to trade?
Agios Pharmaceuticals, Inc. (AGIO) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade AGIO options?
Buying a single AGIO call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade AGIO or any security. Do your own research.
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. (AGIO) operates in the Biotechnology industry. The "About Agios Pharmaceuticals, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Agios Pharmaceuticals, Inc. pay a dividend?
Agios Pharmaceuticals, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Agios Pharmaceuticals, Inc. next report earnings?
Agios Pharmaceuticals, Inc.'s next earnings are expected around July 30, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to AGIO
Comparing AGIO with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 88 Sidney Street, Cambridge, MA, 02139, United States
- Industry
- Biotechnology
- Employees
- 539
- CEO
- Mr. Brian M. Goff M.B.A.
- Phone
- 617 649 8600
- Website
- www.agios.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.